ScreenerHero

ACIUAC Immune SA

NAS · US · Healthcare · Biotechnology · acimmune.com
2.900USDMkt Cap: 288.34M $P/E: —

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap288.34M $
Enterprise Value217.08M $
Revenue (TTM)17.51M $
Gross Profit-28.41M $
Net Income (TTM)-70.45M $
Revenue/Share0.1730 USD
Last Price2.900 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees90
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINCH0329023102
Valuation
P/E (Trailing)—
P/E (Forward)4.68
PEG—
EV/EBITDA-5.11
EV/Revenue12.40
P/S16.47
P/B6.66
EPS (TTM)-0.54
EPS (Forward)0.62
52W Range
2.66084% of range2.945
52W High2.945 USD
52W Low2.660 USD
Profitability
Gross Margin-162.23%
Oper. Margin7.89%
EBITDA Margin-242.61%
Profit Margin-1971.65%
ROE-156.95%
ROA-45.67%
Growth
Revenue Growth1057.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-69.26M $
CapEx (TTM)900.00K $
FCF Margin-189.27%
FCF Yield-11.49%
Net Debt-71.25M $
Net Debt/EBITDA1.68
Balance Sheet
Debt/Equity0.10
Current Ratio0.93
Quick Ratio0.89
Book Value/Sh0.4355 USD
Cash/Share0.7580 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.621 USD
Upside (mean)+197.3%
Target Range5.407 USD – 11.98 USD
$5.407+197.3% to mean$11.98
# Analysts4
Ownership
Shares Out.99.43M
Float39.19M
Insiders37.90%
Institutions24.35%
Short Interest
Short Ratio14.7d
Short % Float7.28%
Short % Out.3.49%
Shares Short3.55M
Short (prev mo.)3.38M
Technical
SMA 502.411 (+20.3%)
SMA 2002.862 (+1.3%)
Beta1.57
S&P 52W Chg19.18%
Avg Vol (30d)436.65K
Avg Vol (10d)304.81K
Technical Indicators
RSI (14)70.7
MACD0.0882
MACD Signal0.0389
MACD Hist.+0.0493
BB Upper2.797 USD
BB Middle2.432 USD
BB Lower2.066 USD
BB Width30.03%
ATR (14)0.1472 USD
Vol Ratio (20d)2.04x